ArticleMolecular pharmaceutics2019
Site-Specific Immuno-PET Tracer to Image PD-L1.
Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Site-Specific Labeling of PD-L1 Fab through Disulfide Rebridging for ImmunoPET Imaging.Chemical & biomedical imaging · 2026Article
- Phage-Selected Clickable Gln-Donor Peptide for Lys-Selective Fab Labeling Using Engineered Microbial Transglutaminase.Antibodies (Basel, Switzerland) · 2026Article
- Advances in immunoPET/SPECT imaging: The role of Fab and F(ab')Acta pharmaceutica Sinica. B · 2025Review
- Precision Oncology in Melanoma: Changing Practices.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- Application ofPharmaceuticals (Basel, Switzerland) · 2024Article
- A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma.Current oncology (Toronto, Ont.) · 2024Review
- Affibody-based molecular probeOpen medicine (Warsaw, Poland) · 2024Article
- Noninvasive PET imaging of tumor PD-L1 expression withAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Phenomic Imaging.Phenomics (Cham, Switzerland) · 2023Review
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- Site-specific protein conjugates incorporating Para-Azido-L-Phenylalanine for cellular and in vivo imaging.Methods (San Diego, Calif.) · 2023Article
- Review
- Imaging strategies for monitoring the immune response.Chemical science · 2022Review
- Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display.ACS chemical biology · 2022Article
- Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.Bioconjugate chemistry · 2022Article
- ImmunoPET: harnessing antibodies for imaging immune cells.Molecular imaging and biology · 2022Review
- Molecular Immune Targeted Imaging of Tumor Microenvironment.Nanotheranostics · 2022Review
- Preclinical antibody-PET imaging of PD-L1.Frontiers in nuclear medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
The rapid ascension of immune checkpoint blockade treatments has placed an emphasis on the need for viable, robust, and noninvasive imaging methods for immune checkpoint proteins, which could be of diagnostic value. Immunoconjugate-based positron emission tomography (immuno-PET) allows for sensitive and quantitative imaging of target levels and has promising potential for the noninvasive evaluation of immune checkpoint proteins. However, the advancement of immuno-PET is currently limited by available imaging tools, which heavily rely on full-length IgGs with Fc-mediated effects and are heterogeneous mixtures upon random conjugation with chelators for imaging. Herein, we have developed a site-specific αPD-L1 Fab conjugate with the chelator 1,4,7-triazacyclononane- N, N', N″-triacetic acid (NOTA), enabling radiolabeling for PET imaging, using the amber suppression-mediated genetic incorporation of unnatural amino acid (UAA), p-azidophenylalanine. This Fab conjugate is homogeneous and demonstrated tight binding toward the PD-L1 antigen in vitro. The radiolabeled version,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.